The role of epigenetics in the etiology of cancer progression is being emphasized for the past two decades to check the impact of chromatin modifiers and remodelers. Histone modifications, DNA methylation, chromatin remodeling, nucleosome positioning, regulation by non-coding RNAs and precisely microRNAs are influential epigenetic marks in the field of progressive cancer sub-types. Furthermore, constant epigenetic changes due to hyper or hypomethylation could efficiently serve as effective biomarkers of cancer diagnosis and therapeutic development. Ongoing research in the field of epigenetics has resulted in the resolutory role of various epigenetic markers and their inhibition using specific inhibitors to arrest their key cellular functions in in-vitro and pre-clinical studies. Although, the mechanism of epigenetics in cancer largely remains unexplored. Nevertheless, various advancements in the field of epigenetics have been made through transcriptome analysis and in-vitro genome targeting technologies to unravel the applicability of epigenetic markers for future cancer therapeutics and management. Therefore, this review emphasizes on recent advances in epigenetic landscapes that could be targeted/explored using novel approaches as personalized treatment modalities for cancer containment.

在过去的二十年里，表观遗传学在癌症进展病因学中的作用一直被强调，以检查染色质修饰剂和重塑剂的影响。组蛋白修饰、DNA 甲基化、染色质重塑、核小体定位、非编码 RNA 和精确 microRNA 的调节是进展性癌症亚型领域中具有影响力的表观遗传标记。此外，由于高甲基化或低甲基化导致的持续表观遗传变化可以有效地作为癌症诊断和治疗发展的有效生物标志物。表观遗传学领域正在进行的研究已导致各种表观遗传标记的决定性作用以及使用特定抑制剂对其进行抑制以在体外阻止其关键细胞功能和临床前研究。尽管如此，癌症中表观遗传学的机制在很大程度上仍未被探索。尽管如此，通过转录组分析和体外基因组靶向技术已经在表观遗传学领域取得了各种进展，以揭示表观遗传标记在未来癌症治疗和管理中的适用性。因此，本综述强调了表观遗传领域的最新进展，这些进展可以使用新方法作为癌症遏制的个性化治疗方式进行靶向/探索。